Spiga Ottavia, Gardini Simone, Rossi Nicole, Cicaloni Vittoria, Pettini Francesco, Niccolai Neri, Santucci Annalisa
Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, 53100, Italy.
GenomeUp SRL, Rome, 00199, Italy.
Genes Dis. 2018 Oct 5;6(1):31-34. doi: 10.1016/j.gendis.2018.09.005. eCollection 2019 Mar.
X-ray structure of methyl-CpG binding domain (MBD) of MeCP2, an intrinsically disordered protein (IDP) involved in Rett syndrome, offers a rational basis for defining the spatial distribution for most of the sites where mutations responsible of Rett syndrome, RTT, occur. We have ascribed pathogenicity for mutations of amino acids bearing positively charged side chains, all located at the protein-DNA interface, as positive charge removal cause reduction of the MeCP2-DNA adduct lifetime. Pathogenicity of the frequent proline replacements, outside the DNA contact moiety of MBD, can be attributed to the role of this amino acid for maintaining both unfolded states for unbound MeCP2 and, at the same time, to favor some higher conformational order for stabilizing structural determinants required by protein activity. These hypotheses can be extended to transcription repressor domain, TRD, the other MeCP2-DNA interaction site and, in general, to all the IDP that interact with nucleic acids.
MeCP2的甲基化CpG结合结构域(MBD)是一种与雷特综合征相关的内在无序蛋白(IDP),其X射线结构为定义雷特综合征(RTT)相关突变发生的大多数位点的空间分布提供了合理依据。我们将带正电荷侧链的氨基酸突变归因于致病性,这些突变均位于蛋白质-DNA界面,因为正电荷的去除会导致MeCP2-DNA加合物寿命缩短。在MBD的DNA接触部分之外频繁发生的脯氨酸替代的致病性,可归因于该氨基酸在维持未结合MeCP2的未折叠状态方面的作用,同时有利于一些更高的构象有序性,以稳定蛋白质活性所需的结构决定因素。这些假设可以扩展到转录抑制结构域(TRD),即另一个MeCP2-DNA相互作用位点,并且一般来说,可以扩展到所有与核酸相互作用的IDP。